Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | HPSE | Q9Y251 | 4/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 10/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13054086 | 1.00 | CA12 (0.48) | CA12CA9HPSEMCHR1MAPT | |
| SCHEMBL3746093 | 1.00 | CA12 (0.48) | CA12CA9HPSEMCHR1MAPT | |
| SCHEMBL13054136 | 0.98 | HPSE (0.48) | CA12CA9HPSEMCHR1MAPT | |
| SCHEMBL13054134 | 0.92 | CA12 (0.51) | CA12CA9MCHR1TRPV1KCNH2 | |
| SCHEMBL3748583 | 0.92 | CA12 (0.51) | CA12CA9MCHR1TRPV1KCNH2 | |
| SCHEMBL3748582 | 0.92 | CA12 (0.51) | CA12CA9MCHR1TRPV1KCNH2 | |
| SCHEMBL3751091 | 0.90 | MAPT (0.52) | CA12CA9HPSEMCHR1MAPT | |
| SCHEMBL13054135 | 0.90 | MAPT (0.52) | CA12CA9HPSEMCHR1MAPT | |
| SCHEMBL3751094 | 0.90 | MAPT (0.52) | CA12CA9HPSEMCHR1MAPT | |
| SCHEMBL13054083 | 0.83 | MAPT (0.55) | MCHR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7838543-B2 | Melanin Concentrating Hormone Receptor 1; Obesity; 4'-Fluoro-biphenyl-4-carboxylic acid {2-[(2-dimethylamino-ethyl)-methyl-amino]-benzothiazol-6-yl}amide; 4-Cyclohexyl-N-{2-[(2-dimethylamino-ethyl)-methyl-amino]-benzooxazol-5-yl}-benzamide; 2-aminobenzoxazoles or 2-aminobenzothiazoles | ELI LILLY AND COMPANY (US) | 2010-11-23 | — | — | US | disclosed |
| US-20090170913-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2009-07-02 | — | — | US | disclosed |
| EP-1828177-B1 | NOVEL MCH RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170913-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | CA12 4668/4885CA9 4072/4885HPSE 3887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.